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Hepatitis AIn November 2005, hepatitis A vaccine was funded under the Australian National Immunisation Program
for Aboriginal and Torres Strait Islander (Indigenous) children aged 12–24 months in the targeted juris-
dictions of Queensland, South Australia, Western Australia and the Northern Territory.
We reviewed the epidemiology of hepatitis A from 2000 to 2014 using data from the Australian
National Notifiable Diseases Surveillance System, the National Hospital Morbidity Database, and
Australian Bureau of Statistics causes-of-death data. The impact of the national hepatitis A immunisation
program was assessed by comparison of pre-vaccine (2000–2005) and post-vaccine time periods (2006–
2014), by age group, Indigenous status and jurisdiction using incidence rate ratios (IRR) per 100,000 pop-
ulation and 95% confidence intervals (CI).
The national pre-vaccine notification rate in Indigenous people was four times higher than the non-
Indigenous rate, and declined from 8.41 per 100,000 (95% CI 5.03–11.79) pre-vaccine to 0.85 per
100,000 (95% CI 0.00–1.99) post-vaccine, becoming similar to the non-Indigenous rate. Notification
and hospitalisation rates in Indigenous children aged <5 years from targeted jurisdictions declined in
the post-vaccine period when compared to the pre-vaccine period (notifications: IRR = 0.07; 95% CI
0.04–0.13; hospitalisations: IRR = 0.04; 95% CI 0.01–0.16). As did notification rates in Indigenous people
aged 5–19 (IRR = 0.08; 95% CI 0.05–0.13) and 20–49 years (IRR = 0.06; 95% CI 0.02–0.15) in targeted juris-
dictions. For non-Indigenous people from targeted jurisdictions, notification rates decreased significantly
in children aged <5 years (IRR 0.47; 95% CI 0.31–0.71), and significantly more overall (IRR = 0.43; 95% CI
0.39–0.47) compared to non-Indigenous people from non-targeted jurisdictions (IRR = 0.60; 95% CI 0.56–
0.64).
The national hepatitis A immunisation program has had a significant impact in the targeted population
with relatively modest vaccine coverage, with evidence suggestive of substantial herd protection effects.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Hepatitis A causes significant morbidity globally (affecting
approximately 120 million people annually [1]), with the incidence
of disease usually inversely correlated with level of sanitation and
access to safe drinking water [2–4]. With improving sanitation and
living conditions in Australia, the annual notification rate of hep-
atitis A has declined from 123 notifications per 100,000 population
in 1961 to 1 per 100,000 population in 2014 [5,6]. A number ofperson-to-person and foodborne outbreaks of hepatitis A have
occurred in Australia over the past twenty years, including very
large outbreaks associated with raw oysters (1997) and semi-
dried tomatoes (2009) [7–15].
Hepatitis A vaccine was first registered for use in Australia in
1994 and has since been recommended for high-risk groups [16].
In response to an increasing number of hepatitis A cases and the
death of three Aboriginal and Torres Strait Islander (henceforth
referred to as Indigenous) children in north Queensland, a hepatitis
A immunisation program commenced in February 1999 for all
Indigenous children in this region (north Queensland has a
population of approximately 600,000 people, of which 1.2% are
Indigenous children aged under 5 years) [17,18]. Two doses of
hepatitis A vaccine were scheduled at 18 and 24 months of age,
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age [16,17]. Following the north Queensland program, a rapid
decline in hepatitis A notifications was reported in the Indigenous
and non-Indigenous populations [17].
In November 2005, hepatitis A vaccine was funded under the
Australian National Immunisation Program (NIP) for all Indigenous
children aged 12–24 months residing in four of the eight states and
territories of Australia, namely Queensland, South Australia, Wes-
tern Australia and the Northern Territory, due to a high risk of
acquiring hepatitis A and hospitalisation from it [16]. Two doses
were originally scheduled at 12 months and 18 months of age in
the Northern Territory and Western Australia, and at 18 and
24 months of age in Queensland and South Australia, changing to
12 and 18 months of age in all four jurisdictions in July 2013
[16,19]. Over the period 2006–2010, decreases in hepatitis A noti-
fications in the Indigenous Australian population was reported
[20]. These decreases in targeted jurisdictions occurred in the con-
text of relatively modest hepatitis A vaccination coverage in
Indigenous children before 36 months of age, with two-dose cover-
age increasing from 31% in 2007 to 60% in 2013, and one-dose cov-
erage at 71% during 2013 [19,20].
The aim of our study was to review the epidemiology of hepati-
tis A in Australia from 2000 to 2014, focusing on the impact of the
national hepatitis A immunisation program on both the directly
targeted population (Indigenous children in the targeted jurisdic-
tions) and broader herd protection effects Australia-wide.2. Methods
2.1. Study design and study period
We undertook a descriptive epidemiological study, with com-
parison of notifications and hospitalisations in the period before
(2000–2005) and after (2006–2014) the introduction of the tar-
geted hepatitis A immunisation program in Australia.2.2. Data sources
2.2.1. Notifications
Confirmed and probable cases of hepatitis A are notifiable to the
National Notifiable Diseases Surveillance System (NNDSS) under
the public health legislation of each jurisdiction [21]. A confirmed
case of hepatitis A requires either laboratory definitive evidence
(detection of hepatitis A virus by nucleic acid testing); or labora-
tory suggestive evidence (detection of hepatitis A-specific
immunoglobulin M antibodies in the absence of recent vaccina-
tion) plus clinical evidence; or laboratory suggestive evidence plus
epidemiological evidence (contact between two people involving a
plausible mode of transmission at a time when one of them is
likely to be infectious and the other has an illness that started
within 15–50 days after this contact and at least one case in the
chain of epidemiologically linked cases is laboratory confirmed)
[22]. A probable case requires clinical evidence plus epidemiologi-
cal evidence [22].
For this analysis, notification data included all confirmed and
probable cases of hepatitis A from the NNDSS with an onset date
between 1 January 2000 and 31 December 2014. For cases with
no recorded onset date, we used the earliest recorded date among
the fields of date of specimen, date of notification, and date when
the notification was received. Variables extracted comprised onset
date, age, sex, jurisdiction of residence, Indigenous status, place of
acquisition, whether died from disease, and vaccination status. The
analysis of the ‘place of acquisition’ data field was restricted to the
years 2010–2014, where data completeness was 80% or greater.2.2.2. Hospitalisations
The National Hospital Morbidity Database (NHMD) is an admin-
istrative database maintained by the Australian Institute of Health
and Welfare. Private and public hospital discharge summaries are
used to capture data relating to administrative, demographic and
clinical information on patients hospitalised in Australia [21].
Using the International Statistical Classification of Disease and
Related Health Problems, 10th Revision, Australian Modification
(ICD-10-AM) code B15 (hepatitis A), all eligible hospital admissions
coded as hepatitis A (either as the principal or other diagnosis) and
with an admission date between 1 January 2000 and 31 December
2013 (latest data available) were included in this analysis.
Variables extracted comprised primary or other diagnosis, date
of admission, age, sex, jurisdiction of residence, Indigenous status,
length of stay (bed days) and mode of separation from hospital.
Jurisdiction of residence and age specific hospitalisation data were
only available between 1 January 2000 and 30 June 2012.
2.2.3. Mortality
Mortality data related to hepatitis A were obtained from the
NNDSS, NHMD and the Australian Bureau of Statistics (ABS). ABS
causes of death data included in this analysis were deaths due to
hepatitis A (ICD-10: code B15) as the primary underlying cause,
for deaths registered between 2007 and 2011 (latest data available).
2.2.4. Population estimates
National, jurisdictional, age-specific and Indigenous-specific
mid-year estimates of resident population sizes were obtained
from the ABS [23].
2.3. Data analysis
We compared notification and hospitalisation rates for two
time periods, i.e. before the introduction of the hepatitis A targeted
immunisation program (pre-vaccine 2000–2005) and after (post-
vaccine 2006-latest available data), and for targeted (Queensland,
South Australia, Western Australia and the Northern Territory)
and non-targeted (New South Wales, Victoria, Tasmania and the
Australian Capital Territory) jurisdictions.
Notification and hospitalisation rates were calculated using ABS
population estimates as the denominator and are presented as age-
specific, jurisdiction-specific, or Indigenous-specific subpopulation
rates per 100,000 population. Descriptive statistics included med-
ian age (and range) and average length of hospital stay. Place of
acquisition for Indigenous and non-Indigenous people was
compared and tested for significance using a Fisher’s exact test.
Age-specific incidence rate ratios (IRR), 95% confidence intervals
(95% CI) and p-values were calculated for Indigenous and
non-Indigenous populations at the national level, and for targeted
and non-targeted jurisdictions, assuming a Poisson distribution. If
the 95% CI for any age-specific or total IRR did not overlap with
the corresponding comparison group, this was considered evidence
of a difference beyond that expected from random variation.
Analyses were conducted using STATA software (version 13.1;
StataCorp, College Station, Texas USA).
Ethical approval was not required as de-identified aggregated
population-based data were used for routine public health surveil-
lance purposes only.3. Results
3.1. Secular trends
A total of 5096 hepatitis A notifications were recorded in the
NNDSS between January 2000 and December 2014, of which
172 C. Thompson et al. / Vaccine 35 (2017) 170–1765004 (98%) were confirmed and 92 (2%) were probable cases. The
overall national notification rate declined from 4.25 per 100,000
in 2000 to 0.97 per 100,000 in 2014, with a nadir of 0.65 per
100,000 in 2011. The national notification rate in Indigenous peo-
ple declined from 8.41 per 100,000 (95% CI 5.03–11.79) during the
pre-vaccine period to 0.85 per 100,000 (95% CI 0.28 to 1.98) dur-
ing the post-vaccine period, while the notification rate in non-
Indigenous people declined from 2.24 per 100,000 (95% CI 1.22–
3.25) pre-vaccine to 1.17 per 100,000 (95% CI 0.71–1.63) post-
vaccine.
In the NHMD, 3398 hospitalisations were recorded between
January 2000 and December 2013 with a diagnosis that included
hepatitis A. The overall national hospitalisation rate declined from
2.31 per 100,000 in 2000 to 0.89 per 100,000 in 2013, with a nadir
of 0.53 per 100,000 in 2012. The national hospitalisation rate in
Indigenous people declined from 4.23 per 100,000 (95% CI 3.52–
4.94) during the pre-vaccine period to 1.09 per 100,000 (95% CI
0.46–1.73) during the post-vaccine period, while the hospitalisa-
tion rate in non-Indigenous people declined from 1.45 per
100,000 (95% CI 0.95–1.96) pre-vaccine to 0.87 per 100,000 (95%
CI 0.62–1.13) post-vaccine. Of the 3398 hospitalisations, 1781
(52%) had hepatitis A identified as the primary diagnosis, with a
median length of stay of 3 days for these 1781 hospitalisations
(range: 1–55 days).
Eight deaths (age range 5–P65 years) were recorded by the ABS
between 2007 and 2011 with hepatitis A as the primary underlying
cause (data available for post-vaccine period only); six of these
deaths were of people aged P65 years. Fewer deaths were
recorded in the other data sources; NNDSS (2000–2014) and
NHMD (2000–2013) captured five deaths each. Matching of deaths
between data sources was not possible using the data fields
available.
3.2. Age and sex distribution
The median age of notified and hospitalised hepatitis A cases in
Australia was similar between the pre-vaccine (notifications:
28 years, range 0–93; hospitalisations: 41 years, range 0–93) and
post –vaccine periods (notifications: 27 years, range 0–97; hospi-
talisations: 41 years, range 0–97). Overall, 6.9% of notified and
2.7% of hospitalised cases were aged <5 years. The average male
to female notification ratio was 1.61:1 (range 1.16:1–2.54:1) in
the pre-vaccine period, and 1.21:1 (range 0.95:1–1.47:1) in the
post-vaccine period.
3.3. Indigenous status
Between 2000 and 2014, 6% (326/5096) of people notified with
hepatitis A were recorded as Indigenous, 77% (3895/5096) as non-
Indigenous and 17% (875/5096) as unknown or missing Indigenous
status. Completeness of this data field was higher for the targeted
jurisdictions (87% complete; 1807/2073) than non-targeted juris-
dictions (80% complete; 2418/3023). Of people hospitalised with
hepatitis A between 2000 and 2013, 6% (196/3398) were recorded
as Indigenous, 92% (3137/3398) as non-Indigenous and 2%
(65/3398) as unknown or missing Indigenous status. Between Jan-
uary 2000 and June 2012, completeness of this data field was
slightly higher for the non-targeted jurisdictions (99% complete;
1877/1899) than targeted jurisdictions (97% complete;
1118/1158).
3.4. Vaccination status
Of all notifications (N = 5096), 13 (0.3%) were reported as fully
vaccinated (three during the pre-vaccine period and ten during
the post-vaccine period), 36 (0.7%) as partially vaccinated (fourduring the pre-vaccine period and 32 during the post-vaccine per-
iod), and 5047 (99%) were of unknown vaccination status.
3.5. Place of acquisition
Of the 882 notifications with a recorded place of acquisition
between 2010 and 2014, 72% (638/882; annual range 56–87%)
were acquired overseas. Common places of overseas acquisition
included the Oceania region (15.2% [134/882]), southern-east Asia
(17.1% [151/882]) and southern-central Asia (21.3% [188/882]).
The proportion of hepatitis A notifications acquired overseas was
significantly higher in non-Indigenous people (73%; 636/874) than
in Indigenous people (25%; 2/8) (p > 0.05).
3.6. Jurisdiction
3.6.1. Targeted jurisdictions (Queensland, Northern Territory, South
Australia and Western Australia)
In the targeted jurisdictions, notifications dropped from 411 in
2000 (rate 2.2 per 100,000) to 73 in 2014 (0.3 per 100,000), and
hospitalisations from 188 in 2000 (1.0 per 100,000) to 24 during
the first half of 2012 (0.1 per 100,000) (Fig. 1). Between 2000
and 2005, Indigenous people residing within targeted jurisdictions
had an 11.6 times higher notification rate, and a 3.9 times higher
hospitalisation rate of hepatitis A than Indigenous people residing
within non-targeted jurisdictions (Table 1).
The notification rate in Indigenous people residing within tar-
geted jurisdictions declined by 93% overall (IRR = 0.07; 95% CI
0.05–0.10) in the post-vaccine period. Age-specific declines were
also identified (Table 1). The overall notification rate in non-
Indigenous people declined by 57% (IRR = 0.43; 95% CI 0.39–0.47)
(Table 1). Hospitalisations in Indigenous people declined by 82%
overall (IRR = 0.18; 95% CI 0.12–0.27). Age-specific declines were
also identified (Table 1). In non-Indigenous people, the overall hos-
pitalisation rate declined by 46% (IRR = 0.54; 95% CI 0.48–0.62)
(Table 1).
The largest decreases in notification and hospitalisation rates
were in the Northern Territory (88% and 86%, respectively) and
Western Australia (70% and 64%, respectively) (Fig. 2).
3.6.2. Non-targeted jurisdictions (New South Wales, Victoria,
Tasmania and the Australian Capital Territory)
Notifications in Indigenous people residing in non-targeted
jurisdictions declined by 53% (IRR = 0.47; 95% CI 0.23–0.95) in
the post-vaccine period. An age-specific decline of 68% was identi-
fied for the 5–19 years age group (IRR = 0.32; 95% CI 0.11–0.95),
while there were no notifications in children aged <5 years during
the entire study period. Notifications in non-Indigenous people
declined by 40% (IRR = 0.60; 95% CI 0.56–0.64). No significant
reduction was identified in the non-Indigenous <5 years age group
(IRR = 0.96; 95% CI 0.69–1.33) (Table 1).
Hospitalisations in Indigenous people declined by 30% however,
this was not statistically significant (IRR = 0.70; 95% CI 0.38–1.27),
while hospitalisations in non-Indigenous people declined by 33%
(IRR = 0.67; 95% CI 0.61–0.73) (Table 1).4. Discussion
In the population directly targeted by the national hepatitis A
immunisation program in Australia (Indigenous children aged
<5 years residing in targeted jurisdictions), we documented signif-
icant declines in hepatitis A notification and hospitalisation rates
(93% and 96%, respectively) between the pre- and post-vaccine
periods. The program also appears to have provided substantial
herd protection to both the Indigenous and non-Indigenous popu-
(a) Noﬁcaon rates for targeted jurisdicons^ 
(b) Noﬁcaon rates for non-targeted jurisdicons~
*Noﬁcaons: January 2000 - December 2014 
# Hospitalisaons: January 2000 - June 2012
^ Targeted jurisdicons: Queensland, South Australia, Western Australia and the Northern Territory 
~ Non-targeted jurisdicons: New South Wales, Victoria, Tasmania and the Australian Capital Territory 
(c) Hospitalisaon rates for targeted jurisdicons^
(d) Hospitalisaon rates for non-targeted jurisdicons~
Fig. 1. Targeted and non-targeted hepatitis A notification (Notifications: January 2000 - December 2014) and hospitalisation (Hospitalisations: January 2000 - June 2012) rates of
Australia, by Indigenous status, age group and year. (a) Notification rates for targeted jurisdictions (Targeted jurisdictions: Queensland, South Australia, Western Australia and the
Northern Territory). (b) Notification rates for non-targeted jurisdictions (Non-targeted jurisdictions: New South Wales, Victoria, Tasmania and the Australian Capital Territory). (c)
Hospitalisation rates for targeted jurisdictions (Targeted jurisdictions: Queensland, South Australia, Western Australia and the Northern Territory). (d) Hospitalisation rates for
non-targeted jurisdictions (Non-targeted jurisdictions: New South Wales, Victoria, Tasmania and the Australian Capital Territory).
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rates declined in the post-vaccine period by 92% for the 5–19 years
Indigenous age group, and by 94% for the 20–49 years age group,
compared to 68% and 33%, respectively, in non-targeted jurisdic-
tions, with the decrease being significantly different to the non-
targeted jurisdictions for the latter age group. In non-Indigenous
people, the notification rate in targeted jurisdictions decreased
by 51% for children aged <5 years, and by 57% overall, with the
overall decrease being significantly different to the overall
decrease in non-targeted jurisdictions.
These decreases in targeted jurisdictions occurred in the con-
text of relatively modest hepatitis A vaccination coverage in
Indigenous children [24,25]. Young children play a key role in
the transmission of hepatitis A to other children and adults, as they
are usually asymptomatic (or only mildly symptomatic) and have
lower levels of personal hygiene [17,18,26]. We also documented
significant, albeit lower, decreases in hepatitis A notifications
between the pre- and post-vaccine periods in both Indigenous
and non-Indigenous populations in non-targeted jurisdictions
(53% and 40%, respectively). These decreases may also be partly
attributable to the targeted national immunisation program, given
the extensive population movement of Indigenous people between
states and territories of Australia [27].The national targeted hepatitis A immunisation program
appears to have been highly effective at reducing the incidence
of disease in Australia. However, the descriptive nature of our
study makes it difficult to quantify the exact contribution of this
program. Of note, the funding of a hepatitis A immunisation pro-
gram in north Queensland from 1999 (with estimated two-dose
coverage of 77% in the Indigenous birth cohort for the year 2000
[17]) may have led us to underestimate the true impact of the
national targeted program. Other factors, including the targeted
immunisation of high-risk groups (such as travellers to hepatitis
A endemic areas, and people with an increased risk of exposure
to hepatitis A based on their occupation or lifestyle) as recom-
mended in the Australian Immunisation Handbook [16], may also
have contributed to the declines Australia-wide. However, avail-
able information indicates that hepatitis A vaccination coverage
of adults in high-risk groups such as travellers to hepatitis A ende-
mic areas, although recommended since 1994, is relatively low
[28,29]. More general limitations of the data we analysed are that
hepatitis A notifications may underestimate true incidence, partic-
ularly in young children, and may be influenced by changes in
diagnostic and public health follow-up practices over time and
across jurisdictions, while hospitalisation data can be influenced
by access to hospital care, changes in admission practices, and cod-
Table 1
Hepatitis A notifications and hospitalisations, by age group, Indigenous status and pre-/post-vaccine period, Australia, 2000–2014; rates, counts and incidence rate ratios (95% CI).
Age group
(years)













(a) Targeted jurisdictions: Queensland, South Australia, Western Australia and the Northern Territory
Notifications <5 2.09 (55) 33.91 (90) 0.99 (46) 2.41 (10) 0.49 (0.33–0.73) 0.07 (0.04–0.13)
5–19 2.24 (194) 18.37 (120) 1.33 (185) 1.46 (16) 0.59 (0.48–0.73) 0.08 (0.05–0.13)
20–49 3.30 (604) 6.13 (48) 1.30 (404) 0.38 (5) 0.39 (0.35–0.45) 0.06 (0.02–0.15)
50–64 1.63 (116) 2.36 (3) 0.66 (88) 0.81 (2) 0.41 (0.31–0.54) 0.29 (0.05–1.73)
P65 1.01 (52) 0.00 (0) 0.35 (33) 0.98 (1) 0.34 (0.22–0.52) –
Total 2.44 (1021) 13.85 (261) 1.04 (756) 1.08 (34) 0.43 (0.39–0.47) 0.07 (0.05–0.10)
Hospitalisations <5 0.19 (5) 16.99 (45) 0.26 (9) 0.62 (2) 1.45 (0.49–4.33) 0.04 (0.01–0.16)
5–19 0.54 (47) 5.26 (35) 0.43 (44) 1.04 (8) 0.82 (0.54–1.23) 0.18 (0.09–0.40)
20–49 1.95 (359) 4.51 (35) 0.89 (200) 1.72 (16) 0.46 (0.39–0.55) 0.37 (0.20–0.66)
50–64 1.53 (108) 1.54 (2) 0.88 (87) 0.00 (0) 0.61 (0.46–0.81) –
P65 1.76 (91) 0.00 (0) 0.94 (65) 0.00 (0) 0.55 (0.40–0.76) –
Total 1.45 (610) 6.20 (117) 0.77 (405) 1.15 (26) 0.54 (0.48–0.62) 0.18 (0.12–0.27)
Age group
(years)













(b) Non-targeted jurisdictions: New South Wales, Victoria, Tasmania and the Australian Capital Territory
Notifications <5 1.21 (55) 0.00 (0) 1.23 (92) 0.00 (0) 0.96 (0.69–1.33) –
5–19 2.21 (319) 1.96 (10) 1.79 (393) 0.57 (5) 0.81 (0.70–0.94) 0.32 (0.11–0.95)
20–49 2.89 (907) 1.09 (6) 1.43 (720) 0.70 (7) 0.50 (0.46–0.56) 0.67 (0.23–1.99)
50–64 1.12 (133) 0.00 (0) 0.77 (164) 0.86 (2) 0.69 (0.55–0.87) –
P65 1.07 (102) 2.07 (1) 0.64 (107) 0.00 (0) 0.59 (0.45–0.78) –
Total 2.12 (1516) 1.19 (17) 1.25 (1476) 0.55 (14) 0.60 (0.56–0.64) 0.47 (0.23–0.95)
Hospitalisations <5 0.18 (8) 1.48 (3) 0.23 (12) 0.00 (0) 1.28 (0.52–3.14) –
5–19 0.53 (77) 0.81 (4) 0.61 (99) 0.28 (1) 1.18 (0.87–1.58) 0.20 (0.02–1.80)
20–49 1.79 (562) 2.50 (14) 1.01 (383) 2.08 (15) 0.60 (0.52–0.68) 0.88 (0.42–1.82)
50–64 1.56 (185) 0.90 (1) 1.15(177) 1.99 (4) 0.76 (0.62–0.93) 2.67 (0.30–23.88)
P65 2.22 (211) 2.34 (1) 1.19 (142) 0.00 (0) 0.54 (0.44–0.67) –
Total 1.45 (1043) 1.61 (23) 0.94 (813) 1.10 (20) 0.67 (0.61–0.73) 0.70 (0.38–1.27)
N = number of cases.
Bold IRR denote significant reductions (p-value < 0.05).
a Post-vaccine period-Notifications: January 2006-December 2014; Hospitalisations: January 2006-June 2012.
b Comparison of pre- and post-vaccine periods.
c Average annual rate per 100,000 total population.
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and Welfare, all hospitalisation data was included for analyses of
Indigenous status [30]. However, data relating to Indigenous status
from the non-targeted jurisdictions should be interpreted with
caution, as weighted completeness for Indigenous identification
in public hospitals during 2011–12 was below the level considered
acceptable (80%) in Tasmania, the Australian Capital Territory, and
Victoria [30].
Declines in hepatitis A in Indigenous populations following tar-
geted childhood immunisation programs have also been reported
in the United States of America (USA), although without clear evi-
dence of broader herd protection impacts on the non-Indigenous
population [31–34]. However Indigenous Australians make up a
greater proportion (2.4%) of the Australian population than Native
Americans and Alaskan Natives do in the USA (0.9%) [33,35]. Sub-
stantial herd protection effects arising from universal childhood
hepatitis A immunisation programs have been documented in
Israel, Argentina and the USA, with the USA introducing a national
universal program in 2006 following evidence of substantially
higher decreases in incidence in states with universal programs
already in place [36–40]. However, targeted hepatitis A vaccination
programs have generally been estimated to be more cost-effective
in lower incidence settings than universal programs [41]. The
World Health Organization recommends mass vaccination pro-
grams in countries moving from high to intermediate hepatitis A
endemicity, but targeted programs in countries with low endemic-
ity [1]. The USA is the only low endemicity country of similarly
high income to Australia that has introduced a universal childhoodprogram, as of 2011 the hepatitis A notification rate in the USA was
similar to that reported in Australia (0.4 and 0.6 per 100,000,
respectively) despite reasonable vaccination coverage in the USA
among children aged 19–35 months (78–87% one-dose coverage
and 50–57% two dose coverage in 2011) [42]. In most Western
European countries hepatitis A incidence has also declined to
below 1.0 per 100,000, in the context of immunisation programs
targeting only individuals at high risk [43]. Universal routine vac-
cination of children has been associated with increased age of
infection, and hence risk of more severe disease [44,45]. In the con-
text of the targeted Australian immunisation program we found no
change in the median age of notified and hospitalised cases
between pre- and post-vaccine periods.
The relatively low hepatitis A seroprevalence in the Australian
population (approximately 55% in persons aged less than 70 years,
from Victoria during 2008 [46]) leaves a large pool of susceptible
individuals. Non-immune individuals in Australia, and other devel-
oped countries, remain at risk of hepatitis A, particularly when
they travel to endemic countries and during foodborne outbreaks
linked to the global food economy, such as those which occurred
in Australia in 2009, associated with imported semi-dried toma-
toes [9], in the USA in 2013, associated with imported pomegra-
nate arils [37,47], and in Europe, Australia and New Zealand,
associated with raw and frozen berries [7,48–51]. The majority of
hepatitis A cases (ranging from 56% to 87% between 2010 and
2014) in Australia now acquire their infection while travelling to
endemic countries. Increasing hepatitis A vaccine coverage among
travellers will reduce the risk of importation and subsequent sec-
(a) Noﬁcaon rates in pre-vaccine period 2000-2005
       and post vaccine period 2006-2014 
(b) Hospitalisaon rates in pre-vaccine period 2000-2005 
                 and post vaccine period 2006-2012 
Non-targeted: NSW- New South Wales; Vic.- Victoria; ACT- Australian Capital Territory; Tas.- Tasmania 
Targeted: NT- Northern Territory; Qld- Queensland; SA- South Australia; WA- Western Australia 
Fig. 2. Hepatitis A notification and hospitalisation rates by jurisdiction, and pre-/post-vaccine period, Australia, 2000–2014. (a) Notification rates in pre-vaccine period 2000–
2005 and post vaccine period 2006–2014. (b) Hospitalisation rates in pre-vaccine period 2000–2005 and post vaccine period 2006–2012. Non-targeted: NSW - New South
Wales; Vic. - Victoria; ACT - Australian Capital Territory; Tas. - Tasmania. Targeted: NT - Northern Territory; Qld - Queensland; SA - South Australia; WA - Western Australia.
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Australia and further research is needed to inform effective strate-
gies to increase community awareness of hepatitis A vaccines and
access to vaccination services [28,29]. Foodborne outbreaks are
also difficult to prevent, even with rigorous food safety standards
in place, due to the difficulties involved in testing for hepatitis A
virus in imported foodstuffs [52,53]. A universal infant hepatitis
A immunisation program in Australia could help mitigate the
impact of foodborne outbreaks, however, this would involve sub-
stantial cost and take decades to have its full effect.5. Conclusions
In summary, the national hepatitis A immunisation program in
Australia has had a significant impact in the targeted population,
with evidence suggesting a broader herd protection effect. Ongoing
surveillance is required to be sure that the current targeted immu-
nisation strategy is maintaining satisfactory disease control.Authors’ contributions
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